Tag: Ebrahim Delpassand MD
FDA Approves Amendment for PRRT Clinical Trial in Texas
August 2, 2012
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…
READ MORERadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
March 23, 2011
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE